The National Institutes of Health (NIH) is committed to identifying and addressing the challenges that impede people from utilizing available HIV prevention and treatment options. Among these challenges are intersectional stigma and discrimination, which NIH is working to address through its initiatives. Interlocking systems of oppression (e.g., racism, classism, sexism, homophobia, and transphobia) are drivers of HIV-related intersectional stigma and discrimination (HIVISD). A major part of NIH’s commitment is the keystone funding opportunity announcement, “Promoting Reductions in Intersectional StigMa (PRISM) to Improve the HIV Prevention Continuum” that was launched in 2019.

NIMH and NIH partners released (November 23, 2018) the three PRISM RFAs (RFA-MH-19-410/411/412), “Promoting Reductions in Intersectional StigMa (PRISM) to Improve the HIV Prevention Continuum”. A primary objective is to develop and test HIVISD reduction interventions to improve HIV prevention outcomes among target populations in the U.S. and worldwide.

The satellite session has three parts. First, a systematic review of the literature. Second, key findings and takeaways from the three PRISM R01-level clinical trials (R01MH121308/NCT0411495, R01NR019009/NCT04108078, and R01MH121256/NCT04225832). Third, a moderated discussion of findings and vision of the science moving forward. Co-chairs are Gregory Greenwood (NIMH) and Paul Gaist (NIH OAR); and moderator is Anne Stangl (CDC, Global Health Center).